Key clinical point: Anticipating pivotal trials due next week at ACC, investigator-led study shows excellent TAVR results in low risk patients.
Major finding: At one year, cardiovascular-related mortality was 1% and there were no disabling strokes.
Data Source: Investigator-led non-randomized study.
Disclosures: Dr. Waksman reports financial relationships with numerous manufacturers of devices for interventional cardiology including those that produce TAVR devices.
2019 Cardiovascular Research Technologies.
This Week's Must Reads
CVD Event Rates Among Adults with PCSK9 Inhibition, Cardiovasc Drugs Ther; ePub 2019 Feb 11; Colantonio, et al
Statin Adherence & Mortality in Patients with ASCVD, JAMA Cardiol; ePub 2019 Feb 13; Rodriguez, et al
Physician Monitoring & LDL-C Follow-Up Testing , Prev Med; 2019 Apr; Dansinger, Williams, et al
CVD Prevalence in HeFH After Statin Treatment, Atherosclerosis; ePub 2019 Feb 12; Perez-Calahorra, et al
Must Reads in Interventional Cardiology & Surgery
Stroke endovascular therapy: The more you do, the better you do, Sheth SA et al. ISC 2019, Abstract 002
High Bleeding Risk & DES Use in ACS Patients, Am J Cardiol; ePub 2017 Jul 24; Alraies, et al
FDA Approves Avalus Surgical Aortic Valve, Medtronic news release; 2017 Aug 2
FDA Approves Recapturable TAVR System, Medtronic news release; 2016 Oct 26